Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 554


Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status: A Systematic Review and Meta-Analysis of Overall Survival Data.

Butaney M, Satkunasivam R, Goldberg H, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z, Wallis CJD.

Am J Clin Oncol. 2019 Dec 4. doi: 10.1097/COC.0000000000000650. [Epub ahead of print]


Statin use is associated with lower risk of PTEN-null and lethal prostate cancer.

Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA.

Clin Cancer Res. 2019 Nov 21. pii: clincanres.2853.2019. doi: 10.1158/1078-0432.CCR-19-2853. [Epub ahead of print]


Diagnostic properties of total and free prostate-specific antigen to predict overall and clinically significant prostate cancer among men with low testosterone and prior negative biopsy.

Schwarzman LS, Pagani RL, Ohlander SJ, Mima M, Abern MR, Andriole GL, Freedland SJ, Moreira DM.

Urology. 2019 Nov 13. pii: S0090-4295(19)30972-0. doi: 10.1016/j.urology.2019.11.004. [Epub ahead of print]


Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools.

Tolksdorf J, Kattan MW, Boorjian SA, Freedland SJ, Saba K, Poyet C, Guerrios L, De Hoedt A, Liss MA, Leach RJ, Hernandez J, Vertosick E, Vickers AJ, Ankerst DP.

BMC Med Res Methodol. 2019 Oct 15;19(1):191. doi: 10.1186/s12874-019-0839-0.


Reply by Authors.

Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

J Urol. 2019 Oct 14:10109701JU000060407644320a0. doi: 10.1097/01.JU.0000604076.44320.a0. [Epub ahead of print] No abstract available.


High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.

Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, DʼAmico AV, Kantoff PW, Bradner JE, Mucci LA, Chavarro JE, Loda M, Brown M.

Nat Commun. 2019 Sep 25;10(1):4358. doi: 10.1038/s41467-019-12298-z.


Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.

Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM.

Clin Cancer Res. 2019 Nov 15;25(22):6721-6730. doi: 10.1158/1078-0432.CCR-19-1587. Epub 2019 Sep 12.


The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder.

Kerr PS, Freedland SJ, Williams SB.

Expert Rev Mol Diagn. 2019 Sep 9:1-3. doi: 10.1080/14737159.2019.1665509. [Epub ahead of print] No abstract available.


Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Allott EH, Csizmadi I, Howard LE, Muller RL, Moreira DM, Andriole GL, Roehrborn CG, Freedland SJ.

BJU Int. 2019 Sep 3. doi: 10.1111/bju.14905. [Epub ahead of print]


Racial Discrepancies in Overall Survival among Men Treated with 223Radium.

Zhao H, Howard L, De Hoedt A, Terris MK, Amling C, Kane C, Cooperberg M, Aronson W, Klaassen Z, Polascik TJ, Vidal AC, Freedland S.

J Urol. 2019 Sep 3:101097JU0000000000000524. doi: 10.1097/JU.0000000000000524. [Epub ahead of print]


Serum Lipids Prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.

Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

J Urol. 2019 Aug 20:101097JU0000000000000494. doi: 10.1097/JU.0000000000000494. [Epub ahead of print]


Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.

Huo J, Ray-Zack MD, Shan Y, Chamie K, Boorjian SA, Kerr P, Jana B, Freedland SJ, Kamat AM, Mehta HB, Williams SB.

Eur Urol Oncol. 2019 Sep;2(5):497-504. doi: 10.1016/j.euo.2018.07.009. Epub 2018 Aug 17.


Dietary intake and prostate cancer, continued pursuit for evidence.

Lin PH, Freedland SJ.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S246-S249. doi: 10.21037/tau.2019.01.08. No abstract available.


Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Tablazon IL, Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ, Williams SB.

Cancer. 2019 Nov 15;125(22):4003-4010. doi: 10.1002/cncr.32414. Epub 2019 Aug 7.


Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy.

Vidal AC, Howard LE, Wiggins E, De Hoedt AM, Shiao SL, Knott S, Taioli E, Fowke JH, Freedland SJ.

Cancer Epidemiol. 2019 Oct;62:101578. doi: 10.1016/j.canep.2019.101578. Epub 2019 Aug 1.


Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.

Wang J, Xu W, Mierxiati A, Huang Y, Wei Y, Lin G, Dai B, Freedland SJ, Qin X, Zhu Y, Ye DW.

Prostate. 2019 Sep;79(13):1563-1571. doi: 10.1002/pros.23878. Epub 2019 Aug 2.


Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-Analysis.

Wallis CJD, Satkunasivam R, Butaney M, Khan UA, Goldberg HA, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

Am J Clin Oncol. 2019 Sep;42(9):711-716. doi: 10.1097/COC.0000000000000577.


The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population.

Skove SL, Howard LE, Senechal J, De Hoedt A, Bresee C, Cunningham TJ, Barbour KE, Kim J, Freedland SJ, Anger JT.

Neurourol Urodyn. 2019 Sep;38(7):1966-1972. doi: 10.1002/nau.24100. Epub 2019 Jul 14.


Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH.

Hanyok BT, Everist MM, Howard LE, De Hoedt AM, Aronson WJ, Cooperberg MR, Kane CJ, Amling CL, Terris MK, Freedland SJ.

Asian J Urol. 2019 Jul;6(3):242-248. doi: 10.1016/j.ajur.2019.01.004. Epub 2019 Jan 18.


Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?

Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Clin Genitourin Cancer. 2019 Oct;17(5):e930-e938. doi: 10.1016/j.clgc.2019.05.007. Epub 2019 May 24.


Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.

Wei Y, Wu J, Gu W, Qin X, Dai B, Lin G, Gan H, Freedland SJ, Zhu Y, Ye D.

Eur Urol. 2019 Sep;76(3):280-283. doi: 10.1016/j.eururo.2019.06.004. Epub 2019 Jun 24.


Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.

Canter DJ, Freedland S, Rajamani S, Latsis M, Variano M, Halat S, Tward J, Cohen T, Stone S, Schlomm T, Bishoff J, Bardot S.

Prostate Cancer Prostatic Dis. 2019 Jun 27. doi: 10.1038/s41391-019-0159-9. [Epub ahead of print]


Obesity, visceral adiposity, and prostate cancer: What is the role of lifestyle interventions?

Shirazipour CH, Freedland SJ.

Cancer. 2019 Aug 15;125(16):2730-2731. doi: 10.1002/cncr.32165. Epub 2019 Jun 10. No abstract available.


Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.

Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB.

JAMA Surg. 2019 Jun 5:e191629. doi: 10.1001/jamasurg.2019.1629. [Epub ahead of print]


Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE.

JAMA Oncol. 2019 Jul 1;5(7):975-983. doi: 10.1001/jamaoncol.2019.0826.


African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K.

J Urol. 2019 Aug;202(2):247-255. doi: 10.1097/JU.0000000000000193. Epub 2019 Jul 8.


Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy.

Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2019 Sep 1;125(17):3025-3032. doi: 10.1002/cncr.32168. Epub 2019 May 1.


Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer.

Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):633-635. doi: 10.1038/s41391-019-0146-1. Epub 2019 Apr 29.


Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.

Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ.

Cancer. 2019 Aug 15;125(16):2861-2867. doi: 10.1002/cncr.32141. Epub 2019 Apr 29. Erratum in: Cancer. 2019 Dec 15;125(24):4544.


Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men.

Vidal AC, Oyekunle T, Howard LE, Shivappa N, De Hoedt A, Figueiredo JC, Taioli E, Fowke JH, Lin PH, Hebert JR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):580-587. doi: 10.1038/s41391-019-0143-4. Epub 2019 Apr 12.


Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.

Freitas D, Andriole GL, Freedland SJ, Neto BS, Moreira DM.

Urology. 2019 Jul;129:160-164. doi: 10.1016/j.urology.2019.02.034. Epub 2019 Mar 23.


MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):531-538. doi: 10.1038/s41391-019-0134-5. Epub 2019 Feb 25.


Blood and dietary magnesium levels are not linked with lower prostate cancer risk in black or white men.

Fowke JH, Koyama T, Dai Q, Zheng SL, Xu J, Howard LE, Freedland SJ.

Cancer Lett. 2019 May 1;449:99-105. doi: 10.1016/j.canlet.2019.02.023. Epub 2019 Feb 15.


The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens.

Freitas DMO, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM.

Scand J Urol. 2018 Oct - Dec;52(5-6):328-332. doi: 10.1080/21681805.2018.1551244. Epub 2019 Feb 14.


First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ.

Cancer Causes Control. 2019 Mar;30(3):259-269. doi: 10.1007/s10552-019-1133-5. Epub 2019 Jan 30.


A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.

Freedland SJ, Howard L, Allen J, Smith J, Stout J, Aronson W, Inman BA, Armstrong AJ, George D, Westman E, Lin PH.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):428-437. doi: 10.1038/s41391-019-0126-5. Epub 2019 Jan 21.


Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.

Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

JAMA Oncol. 2019 Apr 1;5(4):529-536. doi: 10.1001/jamaoncol.2018.5904.


Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database.

Everist MM, Howard LE, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Urol Oncol. 2019 Apr;37(4):289.e11-289.e17. doi: 10.1016/j.urolonc.2018.12.004. Epub 2018 Dec 28.


Rapid Next-Generation Sequencing Method for Prediction of Prostate Cancer Risks.

Fofanov VY, Upadhyay K, Pearlman A, Loke J, O V, Shao Y, Freedland S, Ostrer H.

J Mol Diagn. 2019 Jan;21(1):49-57. doi: 10.1016/j.jmoldx.2018.07.007. Epub 2018 Dec 12.


Interplay between exercise and BMI; results from an equal access, racially diverse biopsy study.

Michael J, Oyekunle T, Howard L, De Hoedt A, Hoyo C, Grant D, Freedland S.

Cancer Causes Control. 2019 Jan;30(1):13-20. doi: 10.1007/s10552-018-1104-2. Epub 2018 Dec 6.


ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.


Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?

Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ.

Cancer. 2019 Feb 1;125(3):434-441. doi: 10.1002/cncr.31808. Epub 2018 Nov 14.


Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K.

Prostate Cancer Prostatic Dis. 2019 May;22(2):292-302. doi: 10.1038/s41391-018-0103-4. Epub 2018 Oct 26.


Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.

Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ.

Clin Genitourin Cancer. 2019 Feb;17(1):e140-e149. doi: 10.1016/j.clgc.2018.09.020. Epub 2018 Oct 4.


Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ; SEARCH Database Study Group.

BJU Int. 2019 Jul;124(1):69-75. doi: 10.1111/bju.14594. Epub 2018 Nov 16.


The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141.


Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.

Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ.

Prostate Cancer Prostatic Dis. 2019 May;22(2):252-260. doi: 10.1038/s41391-018-0095-0. Epub 2018 Oct 2.


Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.

Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ.

Int J Urol. 2018 Dec;25(12):998-1004. doi: 10.1111/iju.13806. Epub 2018 Sep 25.


Enzalutamide treatment for the whole spectrum of CRPC.

Zhao H, Freedland S.

Nat Rev Urol. 2018 Nov;15(11):663-665. doi: 10.1038/s41585-018-0090-1. No abstract available.


Supplemental Content

Loading ...
Support Center